HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

AbstractPURPOSE:
CDP860 is an engineered Fab' fragment-polyethylene glycol conjugate, which binds to and blocks the activity of the beta-subunit of the platelet-derived growth factor receptor (PDGFR-beta). Studies in animals have suggested that PDGFR-beta inhibition reduces tumor interstitial fluid pressure, and thus increases the uptake of concomitantly administered drugs. The purpose of this study was to determine whether changes in tumor vascular parameters could be detected in humans, and to assess whether CDP860 would be likely to increase the uptake of a concurrently administered small molecule in future studies.
PATIENTS AND METHODS:
Patients with advanced ovarian or colorectal cancer and good performance status received intravenous infusions of CDP860 on days 0 and 28. Patients had serial dynamic contrast-enhanced magnetic resonance imaging studies to measure changes in tumor vascular parameters.
RESULTS:
Three of eight patients developed significant ascites, and seven of eight showed evidence of fluid retention. In some patients, the ratio of vascular volume to total tumor volume increased significantly (P < .001) within 24 hours following CDP860 administration, an effect suggestive of recruitment of previously non-functioning vessels.
CONCLUSION:
These observations suggest that inhibition of PDGFR-beta might improve delivery of a concurrently administered therapy. However, in cancer patients, further exploration of the dosing regimen of CDP860 is required to dissociate adverse effects from beneficial effects. The findings challenge the view that inhibition of PDGF alone is beneficial, and confirm that effects of PDGFR kinase inhibition mediate, to some extent, the fluid retention observed in patients treated with mixed tyrosine kinase inhibitors.
AuthorsG C Jayson, G J M Parker, S Mullamitha, J W Valle, M Saunders, L Broughton, J Lawrance, B Carrington, C Roberts, B Issa, D L Buckley, S Cheung, K Davies, Y Watson, K Zinkewich-Péotti, L Rolfe, A Jackson
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 23 Issue 5 Pg. 973-81 (Feb 10 2005) ISSN: 0732-183X [Print] United States
PMID15466784 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CDP860
  • Contrast Media
  • Immunoglobulin Fab Fragments
  • Polyethylene Glycols
  • Receptor, Platelet-Derived Growth Factor beta
Topics
  • Adult
  • Aged
  • Ascites (etiology)
  • Capillary Permeability (physiology)
  • Colonic Neoplasms (blood supply)
  • Contrast Media
  • Extracellular Fluid (metabolism)
  • Female
  • Follow-Up Studies
  • Humans
  • Image Processing, Computer-Assisted (methods)
  • Immunoglobulin Fab Fragments (administration & dosage, adverse effects, therapeutic use)
  • Magnetic Resonance Imaging (methods)
  • Male
  • Middle Aged
  • Ovarian Neoplasms (blood supply)
  • Pleural Effusion (etiology)
  • Polyethylene Glycols (administration & dosage, adverse effects, therapeutic use)
  • Receptor, Platelet-Derived Growth Factor beta (antagonists & inhibitors)
  • Rectal Neoplasms (blood supply)
  • Regional Blood Flow (physiology)
  • Tumor Burden

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: